Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
CA 2528160 C · Owner: Agy Therapeutics, Inc. · Inventors: Urfer, Roman; Oksenberg, Donna
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor wherein , the ligand is preferably SA-4503 or salts, or solvates thereof These , molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke diabetic peripheral neuropathy, cancer therapy induced neuropathy multiple , sclerosis, amyotrophic lateral sclerosis traumatic brain injury, spinal cord , injury Huntington's disease or Parkinson's disease. In other methods the , sigma …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 14, 2004 and granted January 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 14, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 14, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.